Many traumatic brain injuries result in significant communication impairment across a spectrum that can range from limited speaking to apparent disorders of consciousness such as comas.
|Slideshows|April 18, 2016
Depression Research Update: April 2016
Author(s)Mark L. Fuerst
The studies discussed in this slideshow assess the benefits of non-traditional therapies for depressive disorders.
Advertisement
References:
1. Falconer CJ, Rovira A, King JA, et al.
2. Macy RJ, Jones E, Graham LM, Roach L.
3. Centre for Addiction and Mental Health.
Advertisement
Related to this article
Review the timeline for Igalmi in at-home treatment of agitation in bipolar disorder and schizophrenia.
Meta-analysis finds bright light therapy boosts remission and response in nonseasonal depression, offering a low-cost add-on to standard care.
Minerva Neurosciences webinar reported that roluperidone monotherapy improved primary negative symptoms and functioning in stable patients with schizophrenia who had a low relapse risk.
Teacher-recorded classroom engagement scores beat GPA at identifying middle schoolers who reported alcohol or cannabis use by eighth grade.
The FDA seems to have shelved the fast-track drug review initiative launched during the Trump administration.
Oveporexton (Orzeyful) is now available in the US by prescription for the treatment of narcolepsy type 1.
Explore the types of scams encountered in psychiatric practice in order to help identify those at risk.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Major Depressive Disorder With Mixed Features: Diagnosis and Treatment
2
New National Guidance for Managing Medetomidine Intoxication and Withdrawal
3
FDA Shelves Fast-Track Drug Review Initiative
4
Ahead of the FDA Action Date: A Timeline of Igalmi for Agitation in Bipolar Disorder and Schizophrenia
5